SCHEMBL24711544

SCHEMBL24711544

CC(C)(C)OC(=O)N1CCC[C@@](C)(O)C1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.45
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
EPHX1 P07099 1/20 0.40
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
PREP P48147 1/20 0.38
EPHX2 P34913 1/20 0.38
NR1H2 P55055 1/20 0.38
CYP11B2 P19099 1/20 0.38
CTSK P43235 1/20 0.37
RECQL P46063 1/20 0.37
USP30 Q70CQ3 1/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24095376 1.00 HPGD (0.45) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL3940936 1.00 HPGD (0.45) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31460589 0.95 HPGD (0.48) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31603608 0.95 HPGD (0.48) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31460689 0.95 HPGD (0.48) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL25286793 0.90 USP2 (0.47) HPGDUSP2SMN1; SMN2EPHX1MAPT
SCHEMBL2218646 0.90 USP2 (0.47) HPGDUSP2SMN1; SMN2EPHX1MAPT
SCHEMBL5524618 0.87 HPGD (0.49) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL12683369 0.86 HPGD (0.47) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL14801055 0.86 USP2 (0.50) HPGDUSP2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026047575-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2026-03-05 WO disclosed
WO-2025087282-A1 METHOD FOR PREPARING CHIRAL ALCOHOL COMPOUND 中国科学院上海有机化学研究所 2025-05-01 WO disclosed
CN-119899090-A Preparation method of chiral alcohol compound 中国科学院上海有机化学研究所 2025-04-29 CN disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
WO-2022258986-A1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER Argonaut Therapeutics Limited (GB) 2022-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 HPGD 987/4885USP2 2291/4885SMN1; SMN2 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.